Janux Therapeutics JANX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $13.73M+47.1% | $10M-5.6% | $10M-23.4% | $439K-97.1% | $9.34M+28.1% | ||
| $127.65M+60.8% | $125.9M+84.1% | $115.15M+92.5% | $99.14M+86.7% | $79.37M+49.4% | ||
| $43.06M-1.1% | $41.77M+1.8% | $39.13M-0.1% | $46.18M+65.2% | $43.55M+61.2% | ||
| $170.72M+38.9% | $167.67M+53.2% | $154.29M+55.8% | $145.32M+79.3% | $122.92M+53.4% | ||
| -$156.98M-38.2% | -$157.67M-59.5% | -$144.29M-67.9% | -$144.88M-120% | -$113.58M-55.9% | ||
| -1,143.1%+73.5pp | -1,576.7%-643pp | -1,442.9%-784pp | -33,002.1%-32,566pp | -1,216.6%-217pp | ||
| $42.51M+18.6% | $44.04M+47.5% | $42.39M+66.7% | $39.24M+79.3% | $35.84M+108% | ||
| -$114.48M-47.3% | -$113.63M-64.7% | -$101.9M-68.3% | -$105.64M-140% | -$77.74M-39.8% | ||
| -833.6%-0.9pp | -1,136.3%-485pp | -1,019%-555pp | -24,064%-23,773pp | -832.7%-69.8pp | ||
| -$1.84-36.3% | -$1.83-44.1% | -$1.67-44.0% | -$1.79-98.9% | -$1.35-11.6% | ||
| -$155M-39.0% | -$155.64M-60.8% | -$142.22M-69.5% | -$142.8M-124% | -$111.54M-57.5% | ||
| -1,128.7%+66.0pp | -1,556.4%-642pp | -1,422.2%-779pp | -32,527.8%-32,106pp | -1,194.7%-223pp | ||
| -$156.98M-38.2% | -$157.67M-59.5% | -$144.29M-67.9% | -$144.88M-120% | -$113.58M-55.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Janux Therapeutics's revenue?
- Janux Therapeutics (JANX) generated $13.7M in revenue over the trailing twelve months, up 47.1% year over year.
- Is Janux Therapeutics profitable?
- Janux Therapeutics is not currently profitable: it reported a net loss of $114.5M over the trailing twelve months, a -833.6% net margin.
- What is Janux Therapeutics's earnings per share?
- Janux Therapeutics's diluted EPS over the trailing twelve months is $-1.84.
- Where does Janux Therapeutics's income statement data come from?
- Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
